Makati City, August 16, 2018 - Sandoz Philippines Corporation, the local subsidiary of generics global leader Sandoz, has named Ms. Eleanor Lopez as Country Head effective August 1, 2018. Her appointment marks two important milestones in the company’s history. Lopez is the first Filipino and first woman to be appointed as Country Head of Sandoz Philippines Corporation.
Prior to assuming her new role, Lopez was the Business Franchise Head of Cardiovascular & Ophthalmology for Novartis Healthcare Philippines. Sandoz is a division of the Novartis Group.
Lopez has broad experience in marketing and sales, from successfully launching new products and new indications, defending market position in highly competitive generics-dominated markets, to creating blockbuster pharma products.
A visionary leader with excellent operational skills, Lopez has led many cross-functional teams and helped many talents develop in their respective careers. She specializes in brand management, new product development, marketing effectiveness, strategy formulation, business development, and sales management.
Lopez has more than 30 years of pharmaceutical experience in both ethical and consumer products, serving in various leadership capacities. She was Senior Head of Marketing for Abbott Nutrition, Inc. and Marketing Director for the A. Menarini Group. At Pfizer where she worked for thirteen years, she handled various therapeutic areas and was the Marketing Director for Specialty, Oncology & Vaccines and Marketing Director for Primary Care.
About Sandoz Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2017 sales of USD 10.1 billion. In 2017, our products reached well over 500 million patients. For more information, please visit https://www.sandoz.com/